Analytical Data
-
Gene name
CD7
- Application
-
Alternative Names
CD7；T-cell antigen CD7
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P09564
-
Expression Region
1-180aa
-
AA Sequence
MAGPPRLLLL PLLLALARGL PGALAAQEVQ QSPHCTTVPV GASVNITCST SGGLRGIYLR QLGPQPQDII YYEDGVVPTT DRRFRGRIDF SGSQDNLTIT MHRLQLSDTG TYTCQAITEV NVYGSGTLVL VTEEQSQGWH RCSDAPPRAS ALPAPPTGSA LPDPQTASAL PDPPAASALP
-
Molecular Weight
18 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD7 is a glycoprotein that plays a crucial role in T-cell development and function, primarily expressed on T cells and natural killer (NK) cells. Its involvement in immune responses has drawn considerable attention in immunology and cancer research. Studies have shown that CD7 can act as a co-stimulatory molecule, contributing to T-cell activation and proliferation. Abnormal expression of CD7 has been implicated in various hematological malignancies, including T-cell leukemia. This has led to increased interest in CD7 as a potential therapeutic target for immunotherapeutic approaches. Recombinant CD7 proteins have been developed to explore their potential in enhancing immune responses, as well as to serve as targets for bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies. Understanding the structure and function of CD7 through recombinant protein studies can provide critical insights into its role in T-cell biology and pave the way for novel therapeutic strategies targeting CD7 in cancer and immune disorders. The research surrounding recombinant CD7 proteins has significant implications for advancing cancer immunotherapy and improving patient outcomes.
